GlassScriptPhysician profile
John R Krause
NPI 1508815234
$1,243.08
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $184 · 2021: $192 · 2022: $257 · 2023: $288 · 2024: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $317.44 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $166.24 | 2020-2022 | |
| Janssen Biotech, INC. | $77.54 | 2022-2023 | Darzalex, Imbruvica |
| Genmab U.S., INC. | $72.25 | 2024 | Epkinly |
| Adc Therapeutics America, INC. | $61.52 | 2023 | |
| Acrotech Biopharma INC. | $59.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.32 | 2020 | |
| Glaxosmithkline, LLC. | $45.30 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $42.17 | 2022-2024 | Rezlidhia, Tavalisse |
| Epizyme, INC. | $40.93 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $40.47 | 2023 | Xpovio |
| Morphosys, US INC. | $40.01 | 2023 | Monjuvi |
| Merck Sharp & Dohme LLC | $32.79 | 2024 | Reblozyl, Keytruda |
| Taiho Oncology, INC. | $32.17 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.90 | 2024 | Libtayo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $29.83 | 2023 | Clonoseq |
| Servier Pharmaceuticals LLC | $21.82 | 2024 | |
| Sobi, INC | $20.30 | 2024 | |
| Dova Pharmaceuticals | $19.91 | 2021 | |
| Blueprint Medicines Corporation | $19.85 | 2023 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $17.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Krause listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.